Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer (JCOG1113, FUGA-BT)

Trial Profile

Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer (JCOG1113, FUGA-BT)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
  • Indications Biliary cancer
  • Focus Therapeutic Use
  • Acronyms FUGA-BT
  • Most Recent Events

    • 20 Jan 2018 Primary endpoint (Overall survival) has been met, according to the results presented at the 2018 Gastrointestinal Cancers Symposium
    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
    • 09 May 2017 Planned End Date changed from 8 May 2018 to 8 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top